pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2013-0-2-41-45pulmo-160Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESПопуляционная перестройка Т-лимфоцитов, содержащих хемокиновые рецепторы, у пациентов с хронической обструктивной болезнью легкихChanges in T-lymphocyte population containing chemokine receptors in patients with chronic obstructive pulmonary diseaseКадушкинА. Г.KadushkinA. G.

аспирант кафедры биологической химии 

220116, Республика Беларусь, г. Минск, пр. Дзержинского, 83. Тел.: (37517) 272-67-88.

ШманТ. В.ShmanT. V.

к. б. н., зав. лабораторией иммунологических исследований

223040, Республика Беларусь, Минский р-н, д. Боровляны, ул. Фрунзенская, 43. Тел.: (37517) 265-42-22.

БелевцевМ. В.BelevtsevM. V.

к. б. н., зам. директора по научной работе 

223040, Республика Беларусь, Минский р-н, д. Боровляны, ул. Фрунзенская, 43. Тел.: (37517) 265-48-61.

ИбрагимоваЖ. А.IbragimovaZh. A.

к. б. н., зав. лабораторией биохимических методов исследования

220116, Республика Беларусь, г. Минск, пр. Дзержинского, 83. Тел.: (37517) 278-77-34.

ТагановичА. Д.TaganovichA. D.

д. м. н., проф., зав. кафедрой биологической химии 

220116, Республика Беларусь, г. Минск, пр. Дзержинского, 83. Тел.: (37517) 272-67-64.

УО "Белорусский государственный медицинский университет"BelarusГУ "Республиканский научно-практический центр детской онкологии, гематологии и иммунологии"Belarus201328042013024145Copyright © Кадушкин А.Г., Шман Т.В., Белевцев М.В., Ибрагимова Ж.А., Таганович А.Д., 20132013Кадушкин А.Г., Шман Т.В., Белевцев М.В., Ибрагимова Ж.А., Таганович А.Д.Kadushkin A.G., Shman T.V., Belevtsev M.V., Ibragimova Z.A., Taganovich A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/160

Резюме. Хроническая обструктивная болезнь легких (ХОБЛ) – прогрессирующее заболевание, которое плохо поддается лечению. От 14,7 до 68,6 % случаев ХОБЛ не связаны с курением. Методом проточной цитометрии определено относительное количество Т-лимфоцитов крови, содержащих хемокиновые рецепторы CXCR3 и CCR5. Были обследованы 21 некурящий пациент с ХОБЛ, 20 курящих больных ХОБЛ, 20 здоровых некурящих людей и 21 здоровый курильщик. У некурящих пациентов с ХОБЛ наблюдалось увеличение процента CXCR3+ и CCR5+ Т-лимфоцитов по сравнению со здоровыми некурящими людьми. Установлено также повышение доли Т-клеток, содержащих на своей поверхности рецепторы ССR5 и CXCR3, в общей популяции лимфоцитов крови у курящих пациентов с ХОБЛ по сравнению со здоровыми курящими и некурящими людьми. Результаты исследования свидетельствуют о схожем механизме миграции Т-клеток из кровотока в дыхательные пути у некурящих и курящих пациентов.

Summary. Chronic obstructive pulmonary disease (COPD) is a difficult-to-treat progressive disease. About 14.7–68.6 % of COPD cases are not related to smoking. We examined 21 nonsmokers with COPD, 20 smokers with COPD, 20 healthy nonsmokers and 21 healthy smokers. Relative number of peripheral blood T-lymphocytes containing CCR5 and CXCR3 chemokine receptors was determined by flow cytometry. CXCR3+ and CCR5+ T-cell per cent number was increased in non-smokers with COPD compared with healthy non-smokers. A higher proportion of T-cells containing CCR5 and CXCR3 receptors on the cell surface was also observed in blood of smokers with COPD compared both to healthy smokers and nonsmokers. Our findings suggest similar mechanism of T-cells migration from blood into the airways both in non-smoking and smoking patients.

хроническая обструктивная болезнь легкиххемокиновые рецепторыпроточная цитометрияCXCR3CCR5chronic obstructive pulmonary diseasechemokine receptorsflow cytometryCXCR3CCR5ReferencesSalvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374: 733–743.Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374: 733–743.Murray C.J., Lopez A.D. Alternative projections of mortality and disability by course 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.Murray C.J., Lopez A.D. Alternative projections of mortality and disability by course 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.Halbert R.J., Natoli J.L., Gano A. et al. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 2006; 28 (3): 523–532.Halbert R.J., Natoli J.L., Gano A. et al. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 2006; 28 (3): 523–532.Zhou Y., Wang C., Yao W. et al. COPD in Chinese nonsmokers. Eur. Respir. J. 2009; 33: 509–518.Zhou Y., Wang C., Yao W. et al. COPD in Chinese nonsmokers. Eur. Respir. J. 2009; 33: 509–518.Gunen H., Hacievliyagil S.S., Yetkin O. et al. Prevalence of COPD: First epidemiological study of a large region in Turkey. Eur. J. Intern. Med. 2008; 19 (7): 499–504.Gunen H., Hacievliyagil S.S., Yetkin O. et al. Prevalence of COPD: First epidemiological study of a large region in Turkey. Eur. J. Intern. Med. 2008; 19 (7): 499–504.Кадушкин А.Г., Таганович А.Д. Молекулярно-клеточные механизмы развития хронической обструктивной болезни легких. Воен. мед. 2012; 1: 132–138.Кадушкин А.Г., Таганович А.Д. Молекулярно-клеточные механизмы развития хронической обструктивной болезни легких. Воен. мед. 2012; 1: 132–138.Bonecchi R., Bianchi G., Bordignon P.P. et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 1998; 187 (1): 129–134.Bonecchi R., Bianchi G., Bordignon P.P. et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 1998; 187 (1): 129–134.Wan P., Zhong X.N., He Z.Y. et al. The changes and significance of interleukin-16 and CXC chemokine receptor 3 expression in pulmonary artery of smokers with chronic obstructive pulmonary disease. Zhonghua Nei Ke Za Zhi 2009; 48 (10): 841–845.Wan P., Zhong X.N., He Z.Y. et al. The changes and significance of interleukin-16 and CXC chemokine receptor 3 expression in pulmonary artery of smokers with chronic obstructive pulmonary disease. Zhonghua Nei Ke Za Zhi 2009; 48 (10): 841–845.Freeman С.M., Curtis J.L., Chensue S.W. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am. J. Pathol. 2007; 171 (3): 767–776.Freeman С.M., Curtis J.L., Chensue S.W. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am. J. Pathol. 2007; 171 (3): 767–776.Di Stefano A., Capelli A., Lusuardi M. et al. Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin. Exp. Allergy 2001; 31 (6): 893–902.Di Stefano A., Capelli A., Lusuardi M. et al. Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin. Exp. Allergy 2001; 31 (6): 893–902.Koch A., Gaczkowski M., Sturton G. et al. Modification of surface antigens in blood CD8+ T-lymphocytes in COPD: effects of smoking. Eur. Respir. J. 2007; 29: 42–50.Koch A., Gaczkowski M., Sturton G. et al. Modification of surface antigens in blood CD8+ T-lymphocytes in COPD: effects of smoking. Eur. Respir. J. 2007; 29: 42–50.Bronzyna S., Ahern J., Hodge J. et al. Chemotactic mediators of Th1 T-cell trafficking in smokers and COPD patients. COPD 2009; 6 (1): 4–16.Bronzyna S., Ahern J., Hodge J. et al. Chemotactic mediators of Th1 T-cell trafficking in smokers and COPD patients. COPD 2009; 6 (1): 4–16.World Health Organization. Guidelines for controlling and monitoring the tobacco epidemic. Geneva: WHO; 2008.World Health Organization. Guidelines for controlling and monitoring the tobacco epidemic. Geneva: WHO; 2008.Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global initiative for chronic obstructive lung disease (GOLD); 2011.Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global initiative for chronic obstructive lung disease (GOLD); 2011.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global initiative for chronic obstructive lung disease (GOLD); 2009.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global initiative for chronic obstructive lung disease (GOLD); 2009.Wanger J., Clausen J.L., Coates A. et al. Standartisation of the measurement of lung volumes. Eur. Respir. J. 2005; 26: 511–522.Wanger J., Clausen J.L., Coates A. et al. Standartisation of the measurement of lung volumes. Eur. Respir. J. 2005; 26: 511–522.Smyth L.J., Starkey C., Vestbo J. et al. CD4-regulatory cells in COPD patients. Chest 2007; 132 (1): 156–163.Smyth L.J., Starkey C., Vestbo J. et al. CD4-regulatory cells in COPD patients. Chest 2007; 132 (1): 156–163.Domagala+Kulawik J., Hoser G., Dabrowska M. et al. CD4+ / CD25+ cells in systemic inflammation in COPD. Scand. J. Immunol. 2011; 73 (1): 59–65.Domagala+Kulawik J., Hoser G., Dabrowska M. et al. CD4+ / CD25+ cells in systemic inflammation in COPD. Scand. J. Immunol. 2011; 73 (1): 59–65.Domagala+Kulawik J., Hoser G., Dabrowska M. et al. Fas+ lymphocytes and CD4+ / CD25+ cells in peripheral blood of never smoking patients with chronic obstructive pulmonary disease. Centr. Eur. J. Immunol. 2011; 36 (4): 226–232.Domagala+Kulawik J., Hoser G., Dabrowska M. et al. Fas+ lymphocytes and CD4+ / CD25+ cells in peripheral blood of never smoking patients with chronic obstructive pulmonary disease. Centr. Eur. J. Immunol. 2011; 36 (4): 226–232.Muehlinghaus G., Cigliano L., Huehn S. et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105 (10): 3965–3971.Muehlinghaus G., Cigliano L., Huehn S. et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105 (10): 3965–3971.Inngjerdingen M., Damaj B., Maghazachi A.A. Expression and regulation of chemokine receptors in human natural killer cells. Blood 2001; 97 (2): 367–375.Inngjerdingen M., Damaj B., Maghazachi A.A. Expression and regulation of chemokine receptors in human natural killer cells. Blood 2001; 97 (2): 367–375.Barnes P.J. Distribution of receptor targets in the lung. Proc. Am. Thorac. Soc. 2004; 1 (4): 345–351.Barnes P.J. Distribution of receptor targets in the lung. Proc. Am. Thorac. Soc. 2004; 1 (4): 345–351.Scholten D.J., Canals M., Maussang D. et al. Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol. 2012; 165 (6): 1617–1643.Scholten D.J., Canals M., Maussang D. et al. Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol. 2012; 165 (6): 1617–1643.Кадушкин А.Г., Таганович А.Д. Роль хемокинов в патогенезе хронической обструктивной болезни легких. Мед. журн. 2012; 2: 139–144.Кадушкин А.Г., Таганович А.Д. Роль хемокинов в патогенезе хронической обструктивной болезни легких. Мед. журн. 2012; 2: 139–144.O'Boyle G., Fox C.R., Walden H.R. et al. Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proc. Natl Acad. Sci. USA 2012; 109 (12): 4598–4603.O'Boyle G., Fox C.R., Walden H.R. et al. Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proc. Natl Acad. Sci. USA 2012; 109 (12): 4598–4603.

The authors declare that there are no conflicts of interest present.